Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab vs denosumab for glucocorticoid-induced osteoporosis in rheumatic disease
jRCT1041190127Active, not recruiting
- Sponsor
- Nagoya University Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of romosozumab and denosumab in glucocorticoid-induced osteoporosis (GIOP), rheumatoid arthritis (RA) and rheumatism (3 arms), sponsored by Nagoya University Hospital. Primary endpoint: Lumbar spine BMD percent change at 1 year. Started Feb 2021; status: active, not recruiting.
02
Drugs
romosozumabdenosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)rheumatoid arthritis (RA)rheumatism
Beyond the preview
Go deeper on jRCT1041190127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190127.